Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Retifanlimab for Anal Squamous Cell Carcinoma

Participants will receive retifanlimab during 28-day treatment Cycles and will continue to receive retifanlimab for up to 6 Cycles (up to 12 Cycles with study doctor approval) unless the participant's cancer comes back, have serious side effects and cannot continue study treatment, or the study doctor thinks it is in the participant's best interest to stop.

Official registry: https://clinicaltrials.gov/study/NCT07927998 · Memorial Sloan Kettering Cancer Center · enrollment listed as 25

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Retifanlimab. The registry lists allocation as na. Participants will receive retifanlimab during 28-day treatment Cycles and will continue to receive retifanlimab for up to 6 Cycles (up to 12 Cycles with study doctor approval) unless the participant's cancer comes back, have serious side effects and cannot continue study treatment, or the study doctor thinks it is in the participant's best interest to stop.

They plan to enroll about 25 people at 7 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase II Trial Evaluating Personalized Anal Squamous Cell Carcinoma Treatment Escalation Using Real-Time ctDNA Surveillance (PACER)

Interventions: Retifanlimab

Primary outcome (registry wording): Rate of ctDNA clearance at 12 weeks

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Consent for use of archival tissue and blood draws for research purposes
  • Documentation of Disease
  • o Patients must have pathologically confirmed anal squamous cell carcinoma
  • ° Pathology confirmation of the primary tumor at time of initial diagnosis is acceptable
  • Disease Specific Criteria
  • Patients must have MRD after completion of definitive-CRT defined as:
  • Detectable on the last day of or after completing definitive-CRT

Public study contact (from the registry)

Paul Romesser, MD

646-888-2118

romessep@mskcc.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

FAQ about this NCT record

Is NCT07927998 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07927998?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07927998?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary